ADCs are a unique class of targeted immuno-oncology therapeutics that combines the tumor-targeting selectivity of monoclonal antibodies with the potent antitumor activity of cytotoxic drugs. The ultimate goal of 3rd generation ADCs is to increase their therapeutic index. Read more

Mablink’s expertise covers the development of the 4 key components of an ADC (antibody, antigen, drug and linker). Along with PSARlink technology, Mablink has developed a wide library of drug-linker couples, compatible with any ADC. Read more

Mablink can help you develop your own ADC with optimal physicochemical and pharmacological properties and therapeutic index. PSARlink technology is universal and can be implemented easily into your project at any key milestone. Read more